Advertisement

September 9, 2019

Recardio Begins Phase 2 Trial of Dutogliptin in Early Recovery Postmyocardial Infarction

September 9, 2019—Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its phase 2 study of dutogliptin in combination with filgrastim in early recovery postmyocardial infarction is now enrolling and recruiting in multiple European and United States centers. The clinical study is intended to evaluate the safety and efficacy of the company’s lead candidate, dutogliptin, to restore lost myocardial function in patients who experience ST-segment elevation myocardial infarction and receive percutaneous coronary intervention with stent placement.

Specialized cardiology centers located throughout Europe and the United States have enrolled patients and are actively recruiting. The enrollment of all 140 planned patients will proceed until 2020, such that outcomes will be also available in 2020.

According to Recardio, its regenerative therapeutic approach to minimize and repair the heart muscle injury that occurs after an infarction consists of mobilizing, recruiting, and homing stem cells in vivo by using cytokines and inhibitors. Specifically, engraftment and an improvement in cardiac output are possible by mobilizing bone marrow stem cells into circulating blood with granulocyte colony–stimulating factor and then initiating stem cell migration and homing to cardiac sites of ischemia or injury with dutogliptin.

Dutogliptin is a small-molecule inhibitor of dipeptidyl peptidase-IV, the key enzyme responsible for degradation of stromal-derived factor-1α, which is the major chemokine responsible for mobilization and migration of stem cells to areas of ischemic injury. In addition to its current phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases, including acute myocardial infarction and chronic heart failure, with the goal of improving heart function, quality of life, and survival, stated the company.

Advertisement


September 10, 2019

SURTAVI Compares Completely Percutaneous Approach to TAVR and PCI Versus SAVR and CABG for Intermediate-Risk Patients

September 6, 2019

Occlutech AFR Heart Failure Device Obtains CE Mark Approval